Clinical trials
Allogeneic Stem Cell Transplantation clinical trials
Below are recruiting allogeneic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 377 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT05391490RecruitingPhase 1
Testing donated immune cells for advanced CD19 blood cancers
This early-phase trial tests donated (allogeneic) immune cells engineered to recognize CD19, a target found on many B-cell cancers. It’s designed for people whose CD19+ cancer has come back or didn’t respond after several previous treatments, aiming to shrink tumors and control disease.
LondonAges 16–65 - NCT06765564Recruiting
Study of stem cell therapy for amyotrophic lateral sclerosis (ALS) progression
This study tests whether a new treatment using special motor neuron cells made from stem cells (iPSCs) can help people with ALS. The cells will be transplanted into the spinal cord to try to slow the disease and improve function.
Shanghai, Shanghai MunicipalityAges 18–60 - NCT05147675RecruitingPhase 1
Testing cord stem cell treatment for osteoarthritis safety
This early study (Phase 1) checks whether an infused stem cell product made from donated umbilical cord tissue is safe in people with osteoarthritis. It’s mainly looking for side effects and whether the treatment can be given safely.
Naples, FloridaAges Any age - NCT03173937RecruitingPhase 1/Phase 2
Cord blood transplant for severe aplastic anemia
This study tests a special cord blood transplant that may help your body start making blood cells faster than a regular transplant. It is for people with severe aplastic anemia or related bone marrow failure who have not gotten better with other treatments.
Bethesda, MarylandAges 4–75 - NCT07366658RecruitingPhase 1
Experimental therapy for neuroendocrine tumors that did not respond to treatment
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
BeijingAges 18–75 - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT05400603RecruitingPhase 1
Immunotherapy trial for relapsed neuroblastoma or osteosarcoma
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Atlanta, GeorgiaAges 1 year+ - NCT06442761RecruitingPhase 1
Stem cell collection for sickle cell disease using motixafortide
This trial tests a drug called motixafortide that helps move stem cells from your bone marrow into your blood so they can be collected for future gene therapy. It is for adults with severe sickle cell disease who may benefit from this treatment approach.
Birmingham, AlabamaAges 18 years+ - NCT04959903RecruitingPhase 1/Phase 2
SMART101 after T-cell–depleted bone marrow transplant for blood cancers
This early-phase study tests SMART101 given after a T-cell–depleted (T-cell removed) donor bone marrow transplant. It aims to see if the treatment is safe and can help control certain high-risk blood cancers in children and adults.
New York, New YorkAges Any age - NCT04024761RecruitingPhase 1
NK cell therapy for leukemia relapse after transplant
This Phase 1 study tests whether an infusion of special immune cells (NK cells) from a donor can help control leukemia or related blood cancers that come back or do not fully go away after a stem cell transplant. It also uses short chemotherapy to “make space” for the NK cells to work, and IL-2 to help them function.
Boston, MassachusettsAges 12 years+ - NCT06119256RecruitingPhase 1
TCR-T cells for EBV after stem cell transplant
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
Beijing, Beijing MunicipalityAges 14–75 - NCT06647979RecruitingPhase 1
Gene editing for severe sickle cell or thalassemia
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
Boston, MassachusettsAges 13–40 - NCT06575426RecruitingPhase 1/Phase 2
Pig pancreatic cell transplant for type 1 diabetes
This trial tests a new treatment made from pig pancreatic cells (called OPF-310) that are placed under the skin to help control blood sugar in people with type 1 diabetes. It is for those whose diabetes is difficult to manage and who have dangerous low blood sugar episodes.
Chicago, IllinoisAges 35–70 - NCT05584761RecruitingPhase 1/Phase 2
Cord blood stem cells plus azacitidine for advanced blood cancers
This trial tests whether adding donated cord blood stem cells to azacitidine can improve outcomes for people with advanced MDS, CMML-2, or a certain type of AML. It may help by giving the treatment a stronger chance to control abnormal blood-forming cells.
Nanjing, JiangsuAges 18–80 - NCT06446050RecruitingEarly Phase 1
Modified stem cells for advanced colorectal cancer
This trial tests a new treatment using special stem cells (modified to boost your immune system) for people with advanced colorectal cancer. It is for patients who are 18 or younger and whose cancer has not responded to or cannot be treated with standard therapies.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05773729Recruiting
Gene-modified own stem cell treatment for transfusion-dependent thalassemia
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
ShanghaiAges 3–18 - NCT05776173Recruiting
Gene-modified stem cell treatment for transfusion-dependent thalassemia
This trial tests whether giving you your own (autologous) gene-modified blood stem cells can improve transfusion-dependent beta-thalassemia and its safety. It may help people who do not have a fully matched donor and need an alternative approach to care.
ShanghaiAges 6–35 - NCT06465550RecruitingPhase 1
Gene therapy for beta-thalassemia in children and teens
This trial tests a new gene therapy (BD211) for children and teens with severe beta-thalassemia who need regular blood transfusions. The treatment uses your own blood stem cells, modified with a working gene, to help your body make healthy red blood cells and reduce the need for transfusions.
Guangzhou, GuandongAges 3–35 - NCT06571825RecruitingPhase 4
Comparing transplant vs. venetoclax for older adults with AML
This trial tests whether a reduced-intensity stem cell transplant or venetoclax-based pills work better for patients aged 60-75 with high-risk acute myeloid leukemia who are already in remission.
Hangzhou, ZhejiangAges 60–75 - NCT06655662RecruitingPhase 1
Gene therapy for severe beta-thalassemia
This trial tests a one-time gene therapy using your own blood stem cells to treat severe beta-thalassemia. It may help you stop needing regular blood transfusions.
GuangxiAges 6–35 - NCT07680803RecruitingPhase 2
Gene therapy for transfusion-dependent beta-thalassemia
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
Rome, LazioAges 3–35 - NCT07665021RecruitingPhase 1/Phase 2
Gene therapy for children with severe bone disease
This trial tests a gene therapy that uses a child's own stem cells to treat autosomal recessive osteopetrosis (a genetic bone disease). It aims to improve bone health and reduce complications like fractures and vision loss.
Milan, ItalyAges 4 weeks–2 years - NCT05864170RecruitingEarly Phase 1
Tested injection for severe transfusion-dependent thalassemia
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
Shenzhen, GuangdongAges 18–35
Hear when a new Allogeneic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic stem cell transplantation?
- Yes. Clin2 currently lists 377 recruiting allogeneic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.